Since 2006, the approval of ranibizumab has revolutionized the management of wet age-related macular degeneration (AMD), allowing many patients to maintain or regain their sight. However, despite promising results in controlled clinical trials, real-world application shows a notable gap in efficacy due to challenges in treatment adherence. Monthly eye injections create barriers for patients, leading to missed appointments and under-treatment. Researchers are now exploring innovative solutions to enhance treatment effectiveness and adherence, including drug implants and smarter usage of existing therapies to better support patient needs.
But results in the real world are not as good as they are in clinical trials. And for the most part, scientists think that's because it's too difficult for people to sustain the treatment regimen.
In practice, there are a lot of barriers, says Arshad Khanani. Patients miss appointments and get under-treated.
Collection
[
|
...
]